Episodebeskrivelse
Could Alzheimer’s biomarkers help identify risk years before symptoms appear? Will Tjernlund interviews Dr. Alidad Mirskandari of Niki BioSolutions about Alzheimer’s blood test development, early detection, and the path from clinical research to commercially available diagnostics.
Dr. Mirskandari shares his journey from biology and genetics to an MBA, consulting, Wall Street, and biotech leadership. He explains Niki BioSolutions’ strategy for pharmaceutical biomarker testing services and its work toward a clinical biomarker panel, subject to validation and clinical utility studies.
In this…
Nettsted: nanocappod.com

